Epcoritamab: Tepkinly
Marketing authorisation number: 69481, date marketing authorisation granted: 15/02/2024
We publish synopses from Clinical Study Reports (CSR) to supplement the public information. This provides patients and healthcare providers with the results of our clinical trials and the evidence used to authorise Tepkinly.
Here you can find the CSR synopses after Tepkinly was granted marketing authorisation in Switzerland.
GCT3013-01
Study Indication: Diffuse large B-cell Lymphoma (DLBCL)
Phase: Phase 1/2
Study Name:
A Phase 1/2, Open-Label, Dose Escalation Trial of Epcoritamab in Patients with Relapsed, Progressive or Refractory B-cell Lymphoma.
EudraCT-Number: 2017-001748-36
GTC3013-04
Study Indication: Diffuse large B-cell Lymphoma (DLBCL)
Phase: Phase 1/2
Study Name:
Safety and Preliminary Efficacy of Epcoritamab in Japanese Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
(B-NHL) - A Phase 1/2 Open-Label, Dose-Escalation trial with Expansion Cohorts.JapicCTI-Nummer: Japic-CTI-20540
Unless otherwise specified, all product names appearing in this internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates. No use of any AbbVie trademark, trade name, or trade dress in this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services of the company.
Copyright © 2025 AbbVie Inc. North Chicago, Illinois, U.S.A.